Keywords: Medivation, Astellas, Enzalutamide, Expanded Access Progra, USA, FDA, Prostate cancer
Expanded Access Program for enzalutamide agreed with US FDA
Article | 30 May 2012
The US Food and Drug Administration agreed that Medivation (Nasdaq: MDVN) and Japanese drug major Astellas Pharma (TYO: 4503) may proceed ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- SciClone gains China rights to Zensun's Neucardin
